Etidronate is a bisphosphonate and chelating agent that exhibits anti-osteoporotic, anti-resorptive, and anti-inflammatory activities. Etidronate is clinically used to treat osteoporosis, inhibiting bone calcification and resorption. Etidronate is also commercially used to prevent Ca2+ and mineral deposition. In macrophages, etidronate inhibits production of COX-2 and prostaglandin E2 (PGE2) and decreases levels of IL-6, TNF-α, and IL-1β.
| Cas No. | 7414-83-7 |
|---|---|
| Purity | ≥98% |
| Formula | C2H6Na2O7P2 |
| Formula Wt. | 249.99 |
| Chemical Name | (1-Hydroxyethylidene)bisphosphonic acid disodium salt |
| IUPAC Name | disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]ethyl]phosphinate |
| Synonym | Disodium dihydrogen (1-hydroxyethylidene)bis- [phosphate]; Didronel; Diphos; Etidron |
| Melting Point | >300°C |
| Solubility | Soluble in water (26mg/mL). |
| Appearance | White Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | E7433 MSDS PDF |
|---|---|
| Info Sheet | E7433 Info Sheet PDF |
Asano S, Suzuki A, Itoh M. Etidronate for treatment of osteoporosis. Nihon Rinsho. 2009 May;67(5):938-42. PMID: 19432113.
Lomashvili KA, Monier-Faugere MC, Wang X, et al. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int. 2009 Mar;75(6):617-25. PMID: 19129793.
Suzuki Y, Nishiyama T, Hasuda K, et al. Effect of etidronate on COX-2 expression and PGE(2) production in macrophage-like RAW 264.7 cells stimulated by titanium particles. J Orthop Sci. 2007 Nov;12(6):568-77. PMID: 18040640.
